Trial Summary
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on any investigational agents or anticancer treatments within 2 weeks before starting the study medication.
The treatment, also known as G207, has been tested in humans with malignant gliomas, and no serious side effects directly linked to the treatment were found. Some patients experienced mild symptoms like fever, but these were manageable and resolved with standard care. Overall, the treatment appears to be safe for use in humans.
12345GV20-0251 is unique because it involves the granulocyte colony-stimulating factor (G-CSF), which is known to promote tumor growth and angiogenesis (formation of new blood vessels) in certain cancers. This suggests that GV20-0251 may target the G-CSF/G-CSFR signaling pathway, which is associated with cancer cell survival and growth, making it a novel approach compared to standard treatments.
678910